AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (1.7 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

The Wnt-dependent and Wnt-independent functions of BCL9 in development, tumorigenesis, and immunity: Implications in therapeutic opportunities

Minjie Wua,c,1, Heng Donga,c,1, Chao Xua,c,1, Mengqing Suna,c,, Haojin Gaoa,c, Fangtian Bua,c, Jianxiang Chena,b,c( )
College of Pharmacy and Department of Hepatology, Institute of Hepatology and Metabolic Diseases, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China
Laboratory of Cancer Genomics, Division of Cellular and Molecular Research, National Cancer Centre, Singapore 169610, Singapore
Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China

1 These authors contributed equally to this work.

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

B-cell CLL/lymphoma 9 (BCL9) is considered a key developmental regulator and a well-established oncogenic driver in multiple cancer types, mainly through potentiating the Wnt/β-catenin signaling. However, increasing evidences indicate that BCL9 also plays multiple Wnt-independent roles. Herein, we summarized the updates of the canonical and non-canonical functions of BCL9 in cellular, physiological, or pathological processes. Moreover, we also concluded that the targeted inhibitors disrupt the interaction of β-catenin with BCL9 reported recently.

Keywords

DevelopmentImmunityTumorigenesisTherapeutic targetBCL9Multifaceted functions

References

1

Willis TG, Zalcberg IR, Coignet LJA, et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood. 1998;91(6):1873–1881.
Crossref Google Scholar
2

Chan CJ, Martinet L, Gilfillan S, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014;15(5):431–438.
Crossref Google Scholar
3

Gay DM, Ridgway RA, Müller M, et al. Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer. Nat Commun. 2019;10:723.
Crossref Google Scholar
4

Feng M, Wu Z, Zhou Y, et al. BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer. Signal Transduct Target Ther. 2021;6:313.
Crossref Google Scholar
5

Zhang Y, Zhang Q, Chen H, et al. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway. Life Sci. 2018;208:284–294.
Crossref Google Scholar
6

Hyeon J, Ahn S, Lee JJ, et al. Prognostic significance of BCL9 expression in hepatocellular carcinoma. Korean J Pathol. 2013;47(2):130–136.
Crossref Google Scholar
7

Townsley FM, Thompson B, Bienz M. Pygopus residues required for its binding to Legless are critical for transcription and development. J Biol Chem. 2004;279(7):5177–5183.
Crossref Google Scholar
8

Chen J, Rajasekaran M, Xia H, et al. CDK1-mediated BCL9 phosphorylation inhibits clathrin to promote mitotic Wnt signalling. EMBO J. 2018;37(20):e99395.
Crossref Google Scholar
9

Suzuki K, Okuno Y, Kawashima N, et al. MEF2D-BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents. J Clin Oncol. 2016;34(28):3451–3459.
Crossref Google Scholar
10

Wen Z, Darnell JE. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 1997;25(11):2062–2067.
Crossref Google Scholar
11

Shibuya A, Campbell D, Hannum C, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4(6):573–581.
Crossref Google Scholar
12

Watkins TBK, Lim EL, Petkovic M, et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature. 2020;587(7832):126–132.
Crossref Google Scholar
13

Cantù C, Pagella P, Shajiei TD, et al. A cytoplasmic role of Wnt/β-catenin transcriptional cofactors Bcl9, Bcl9l, and Pygopus in tooth enamel formation. Sci Signal. 2017;10(465):eaah4598.
Crossref Google Scholar
14

Cantù C, Felker A, Zimmerli D, et al. Mutations in Bcl9 and Pygo genes cause congenital heart defects by tissue-specific perturbation of Wnt/β-catenin signaling. Genes Dev. 2018;32(21-22):1443–1458.
Crossref Google Scholar
15

Sloan KE, Stewart JK, Treloar AF, et al. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res. 2005;65(23):10930–10937.
Crossref Google Scholar
16

Li J, Chen X, Ding X, et al. LATS2 suppresses oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction. Cell Rep. 2013;5(6):1650–1663.
Crossref Google Scholar
17

Jiang M, Kang Y, Sewastianik T, et al. BCL9 provides multi-cellular communication properties in colorectal cancer by interacting with paraspeckle proteins. Nat Commun. 2020;11:19.
Crossref Google Scholar
18

Xu W, Zhou W, Cheng M, et al. Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma. Sci Rep. 2017;7:40446.
Crossref Google Scholar
19

Tan Z, Huang Q, Zang J, et al. HIF-1α activates hypoxia-induced BCL-9 expression in human colorectal cancer cells. Oncotarget. 2017;8(16):25885–25896.
Crossref Google Scholar
20

Liu D, Chen C, Cui M, et al. miR-140-3p inhibits colorectal cancer progression and its liver metastasis by targeting BCL9 and BCL2. Cancer Med. 2021;10(10):3358–3372.
Crossref Google Scholar
21

Liu X, Ji Q, Zhang C, et al. miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models. Sci Rep. 2017;7:7113.
Crossref Google Scholar
22

Rao X, Liu X, Liu N, et al. Long noncoding RNA NEAT1 promotes tumorigenesis in H. pylori gastric cancer by sponging miR-30a to regulate COX-2/BCL9 pathway. Helicobacter. 2021;26(6):e12847.
Crossref Google Scholar
23

Jia W, Eneh JO, Ratnaparkhe S, et al. microRNA-30c-2∗ expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9. Mol Cancer Res. 2011;9(12):1732–1745.
Crossref Google Scholar
24

Yang C, Xu Y, Cheng F, et al. miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9. Cell Death Dis. 2017;8(8):e2999.
Crossref Google Scholar
25

Ling XH, Chen ZY, Luo HW, et al. BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression. Oncol Lett. 2016;11(3):2001–2008.
Crossref Google Scholar
26

Zhao JJ, Lin J, Zhu D, et al. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res. 2014;74(6):1801–1813.
Crossref Google Scholar
27

Lv Y, Zhang W, Zhao J, et al. SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer. Signal Transduct Targeted Ther. 2021;6:108.
Crossref Google Scholar
28

Chang C, Rajasekaran M, Qiao Y, et al. The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma. Nat Commun. 2022;13:1363.
Crossref Google Scholar
29

Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. CMLS Cell Mol Life Sci. 2004;61(17):2189–2199.
Crossref Google Scholar
30

Kramps T, Peter O, Brunner E, et al. Wnt/Wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear β-catenin-TCF complex. Cell. 2002;109(1):47–60.
Crossref Google Scholar
31

Liscia DS, Merlo GR, Garrett C, et al. Expression of int-2 mRNA in human tumors amplified at the int-2 locus. Oncogene. 1989;4(10):1219–1224.
Google Scholar
32

von Felden J, Craig AJ, Garcia-Lezana T, et al. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene. 2021;40(1):140–151.
Crossref Google Scholar
33

Eslahi M, Sadoughi F, Asemi Z, et al. Chitosan and Wnt/β-catenin signaling pathways in different cancers. Comb Chem High Throughput Screen. 2021;24(9):1323–1331.
Crossref Google Scholar
34

Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192–1205.
Crossref Google Scholar
35

Dong H, Wang M, Chang C, et al. Erianin inhibits the oncogenic properties of hepatocellular carcinoma via inducing DNA damage and aberrant mitosis. Biochem Pharmacol. 2020;182:114266.
Crossref Google Scholar
36

Li Q, Sun M, Wang M, et al. Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application. Cancer Sci. 2021;112(5):1695–1706.
Crossref Google Scholar
37

Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31(1):99–109.
Crossref Google Scholar
38

Hsieh JC, Kodjabachian L, Rebbert ML, et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature. 1999;398(6726):431–436.
Crossref Google Scholar
39

Hsieh JC, Rattner A, Smallwood PM, et al. Biochemical characterization of Wnt-frizzled interactions using a soluble, biologically active vertebrate Wnt protein. Proc Natl Acad Sci U S A. 1999;96(7):3546–3551.
Crossref Google Scholar
40

Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810.
Crossref Google Scholar
41

Thompson B, Townsley F, Rosin-Arbesfeld R, et al. A new nuclear component of the Wnt signalling pathway. Nat Cell Biol. 2002;4(5):367–373.
Crossref Google Scholar
42

Townsley FM, Cliffe A, Bienz M. Pygopus and Legless target Armadillo/β-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol. 2004;6(7):626–633.
Crossref Google Scholar
43

Belenkaya TY, Han C, Standley HJ, et al. Pygopus encodes a nuclear protein essential for Wingless/Wnt signaling. Development. 2002;129(17):4089–4101.
Crossref Google Scholar
44

Parker DS, Jemison J, Cadigan KM. Pygopus, a nuclear PHD-finger protein required for Wingless signaling in Drosophila. Development. 2002;129(11):2565–2576.
Crossref Google Scholar
45

Sampietro J, Dahlberg CL, Cho US, et al. Crystal structure of a β-catenin/BCL9/Tcf4 complex. Mol Cell. 2006;24(2):293–300.
Crossref Google Scholar
46

Habib SJ, Acebrón SP. Wnt signalling in cell division: from mechanisms to tissue engineering. Trends Cell Biol. 2022;32(12):1035–1048.
Crossref Google Scholar
47

Peifer M, Berg S, Reynolds AB. A repeating amino acid motif shared by proteins with diverse cellular roles. Cell. 1994;76(5):789–791.
Crossref Google Scholar
48

Huber AH, Nelson WJ, Weis WI. Three-dimensional structure of the Armadillo repeat region of β-catenin. Cell. 1997;90(5):871–882.
Crossref Google Scholar
49

Miller TCR, Rutherford TJ, Johnson CM, et al. Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor. J Mol Biol. 2010;401(5):969–984.
Crossref Google Scholar
50

Krieghoff E, Behrens J, Mayr B. Nucleo-cytoplasmic distribution of β-catenin is regulated by retention. J Cell Sci. 2006;119(Pt 7):1453–1463.
Crossref Google Scholar
51

de la Roche M, Worm J, Bienz M. The function of BCL9 in Wnt/β-catenin signaling and colorectal cancer cells. BMC Cancer. 2008;8:199.
Crossref Google Scholar
52

Sustmann C, Flach H, Ebert H, et al. Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with β-catenin. Mol Cell Biol. 2008;28(10):3526–3537.
Crossref Google Scholar
53

Gu Z, Churchman M, Roberts K, et al. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016;7:13331.
Crossref Google Scholar
54

Fuerer C, Homicsko K, Lukashev AN, et al. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells. BMC Cancer. 2006;6:236.
Crossref Google Scholar
55

Acebron S, Karaulanov E, Berger B, et al. Mitotic Wnt signaling promotes protein stabilization and regulates cell size. Mol Cell. 2014;54(4):663–674.
Crossref Google Scholar
56

Huang YL, Anvarian Z, Döderlein G, et al. Maternal Wnt/STOP signaling promotes cell division during early Xenopus embryogenesis. Proc Natl Acad Sci U S A. 2015;112(18):5732–5737.
Crossref Google Scholar
57

Yamamoto H, Sakane H, Yamamoto H, et al. Wnt3a and Dkk1 regulate distinct internalization pathways of LRP6 to tune the activation of β-catenin signaling. Dev Cell. 2008;15(1):37–48.
Crossref Google Scholar
58

Varelas X, Miller BW, Sopko R, et al. The Hippo pathway regulates Wnt/β-catenin signaling. Dev Cell. 2010;18(4):579–591.
Crossref Google Scholar
59

Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130(6):1120–1133.
Crossref Google Scholar
60

Xu T, Wang W, Zhang S, et al. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development. 1995;121(4):1053–1063.
Crossref Google Scholar
61

Justice RW, Zilian O, Woods DF, et al. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995;9(5):534–546.
Crossref Google Scholar
62

Yabuta N, Fujii T, Copeland NG, et al. Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts. Genomics. 2000;63(2):263–270.
Crossref Google Scholar
63

Jang JW, Kim MK, Lee YS, et al. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3. Oncogene. 2017;36(7):999–1011.
Crossref Google Scholar
64

Schuringa JJ, Dekker LV, Vellenga E, et al. Sequential activation of Rac-1, SEK-1/MKK-4, and protein kinase Cδ is required for interleukin-6-induced STAT3 Ser-727 phosphorylation and transactivation. J Biol Chem. 2001;276(29):27709–27715.
Crossref Google Scholar
65

Elsarraj HS, Hong Y, Limback D, et al. BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression. NPJ Breast Cancer. 2020;6:12.
Crossref Google Scholar
66

Darnell Jr JE. STATs and gene regulation. Science. 1997;277(5332):1630–1635.
Crossref Google Scholar
67

Sloan KE, Eustace BK, Stewart JK, et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer. 2004;4:73.
Crossref Google Scholar
68

He W, Wang S, Yan J, et al. Self-assembly of therapeutic peptide into stimuli-responsive clustered nanohybrids for cancer-targeted therapy. Adv Funct Mater. 2019;29(10):1807736.
Crossref Google Scholar
69

Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–249.
Crossref Google Scholar
70

Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964.
Crossref Google Scholar
71

Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–213.
Crossref Google Scholar
72

Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010;16(4):399–403.
Crossref Google Scholar
73

Adachi S, Jigami T, Yasui T, et al. Role of a BCL9-related β-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. Cancer Res. 2004;64(23):8496–8501.
Crossref Google Scholar
74

Brembeck FH, Schwarz-Romond T, Bakkers J, et al. Essential role of BCL9-2 in the switch between β-catenin’s adhesive and transcriptional functions. Genes Dev. 2004;18(18):2225–2230.
Crossref Google Scholar
75

Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003;114(4):457–467.
Crossref Google Scholar
76

Zhao B, Li L, Lei Q, et al. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24(9):862–874.
Crossref Google Scholar
77

Pagella P, Cantù C, Mitsiadis TA. Linking dental pathologies and cancer via Wnt signalling. Oncotarget. 2017;8(59):99213–99214.
Crossref Google Scholar
78

de la Roche M, Bienz M. Wingless-independent association of Pygopus with dTCF target genes. Curr Biol. 2007;17(6):556–561.
Crossref Google Scholar
79

Huge N, Sandbothe M, Schröder AK, et al. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma. Hepatol Int. 2020;14(3):373–384.
Crossref Google Scholar
80

Wisniewski JA, Yin J, Teuscher KB, et al. Structure-based design of 1,4-dibenzoylpiperazines as β-catenin/B-cell lymphoma 9 protein-protein interaction inhibitors. ACS Med Chem Lett. 2016;7(5):508–513.
Crossref Google Scholar
81

Takada K, Zhu D, Bird GH, et al. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med. 2012;4(148):148ra117.
Crossref Google Scholar
82

de la Roche M, Rutherford TJ, Gupta D, et al. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid. Nat Commun. 2012;3:680.
Crossref Google Scholar
83

Fang Y, Kang Y, Zou H, et al. β-elemene attenuates macrophage activation and proinflammatory factor production via crosstalk with Wnt/β-catenin signaling pathway. Fitoterapia. 2018;124:92–102.
Crossref Google Scholar
84

Sun Y, Gao X, Wu P, et al. Jatrorrhizine inhibits mammary carcinoma cells by targeting TNIK mediated Wnt/β-catenin signalling and epithelial-mesenchymal transition (EMT). Phytomedicine. 2019;63:153015.
Crossref Google Scholar
85

Zhai B, Zeng Y, Zeng Z, et al. Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy. Int J Nanomed. 2018;13:6279–6296.
Crossref Google Scholar
86

Zhai B, Zhang N, Han X, et al. Molecular targets of β-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: a review. Biomedecine Pharmacother. 2019;114:108812.
Crossref Google Scholar
87

van Tienen LM, Mieszczanek J, Fiedler M, et al. Constitutive scaffolding of multiple Wnt enhanceosome components by Legless/BCL9. Elife. 2017;6:e20882.
Crossref Google Scholar
88

Miller TCR, Rutherford TJ, Birchall K, et al. Competitive binding of a benzimidazole to the histone-binding pocket of the Pygo PHD finger. ACS Chem Biol. 2014;9(12):2864–2874.
Crossref Google Scholar
89

Fox AH, Lam YW, Leung AKL, et al. Paraspeckles: a novel nuclear domain. Curr Biol. 2002;12(1):13–25.
Crossref Google Scholar
Genes & Diseases
Volume 11 Issue 2,
March 2024
Pages 701-710
DOI: 10.1016/j.gendis.2023.03.012
Cite this article:
Wu M, Dong H, Xu C, et al. The Wnt-dependent and Wnt-independent functions of BCL9 in development, tumorigenesis, and immunity: Implications in therapeutic opportunities. Genes & Diseases, 2024, 11(2): 701-710. https://doi.org/10.1016/j.gendis.2023.03.012

282

Views

3

Downloads

2

Crossref

2

Web of Science

3

Scopus

0

CSCD

Altmetrics
Received: 14 October 2022
Revised: 27 February 2023
Accepted: 05 March 2023
Published: 11 April 2023
© 2023 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return